Putting our best foot forward: Clinical, treatment-based and ethical considerations of nusinersen therapy in Canada for spinal muscular atrophy
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Putting our best foot forward: Clinical, treatment-based and ethical considerations of nusinersen therapy in Canada for spinal muscular atrophy
Authors
Keywords
-
Journal
JOURNAL OF PAEDIATRICS AND CHILD HEALTH
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-09-24
DOI
10.1111/jpc.14226
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CBA and Precaution: Policy-Making about Emerging Technologies
- (2018) Gregory E. Kaebnick et al. HASTINGS CENTER REPORT
- Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
- (2018) Eugenio Mercuri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand
- (2018) John I. McCormick et al. Orphanet Journal of Rare Diseases
- Ethical Challenges Confronted When Providing Nusinersen Treatment for Spinal Muscular Atrophy
- (2018) Alyssa M. Burgart et al. JAMA Pediatrics
- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
- (2017) Richard S. Finkel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Individualised and personalised QALYs in exceptional treatment decisions
- (2016) Warwick Heale JOURNAL OF MEDICAL ETHICS
- An Ethical Framework for Allocating Scarce Life-Saving Chemotherapy and Supportive Care Drugs for Childhood Cancer
- (2016) Yoram Unguru et al. JNCI-Journal of the National Cancer Institute
- Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy
- (2016) Claudia A. Chiriboga et al. NEUROLOGY
- An Ethical Framework for Allocating Scarce Life-Saving Chemotherapy and Supportive Care Drugs for Childhood Cancer
- (2016) Yoram Unguru et al. JNCI-Journal of the National Cancer Institute
- Orphan drug development: an economically viable strategy for biopharma R&D
- (2012) Kiran N. Meekings et al. DRUG DISCOVERY TODAY
- Validation of the Expanded Hammersmith Functional Motor Scale in Spinal Muscular Atrophy Type II and III
- (2011) Allan M. Glanzman et al. JOURNAL OF CHILD NEUROLOGY
- A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation: Figure 1
- (2011) Wim Pinxten et al. JOURNAL OF MEDICAL ETHICS
- Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
- (2010) Y. Hua et al. GENES & DEVELOPMENT
- Can We Afford It?: Ethical Consideration of Expensive Drug Treatment for Neonates and Infants
- (2009) R Zlotnik Shaul et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- QALYs: The Basics
- (2009) Milton C. Weinstein et al. VALUE IN HEALTH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started